School of Pharmacy/Key Laboratory of Xinjiang Phytomedicine Resource and Utilization/School of Medical, Shihezi University, Shihezi, China.
State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.
Biomed Chromatogr. 2024 Oct;38(10):e5987. doi: 10.1002/bmc.5987. Epub 2024 Aug 10.
The traditional formulation Hanchuan zupa granules (HCZPs) have been widely used for controlling coronavirus disease 2019 (COVID-19). However, its active components remain unknown. Here, HCZP components targeting the spike receptor-binding domain (S-RBD) of SARS-CoV-2 were investigated using a surface plasmon resonance (SPR) biosensor-based active ingredient recognition system (SPR-AIRS). Recombinant S-RBD proteins were immobilized on the SPR chip by amine coupling for the prescreening of nine HCZP medicinal herbs. Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) identified gallic acid (GA) and methyl gallate (MG) from Rosa rugosa as S-RBD ligands, with K values of 2.69 and 0.95 μM, respectively, as shown by SPR. Molecular dynamics indicated that GA formed hydrogen bonds with G496, N501, and Y505 of S-RBD, and MG with G496 and Y505, inhibiting S-RBD binding to angiotensin-converting enzyme 2 (ACE2). SPR-based competition analysis verified that both compounds blocked S-RBD and ACE2 binding, and SPR demonstrated that GA and MG bound to ACE2 (K = 5.10 and 4.05 μM, respectively), suggesting that they blocked the receptor and neutralized SARS-CoV-2. Infection with SARS-CoV-2 pseudovirus showed that GA and MG suppressed viral entry into 293T-ACE2 cells. These S-RBD inhibitors have potential for drug design, while the findings provide a reference on HCZP composition and its use for treating COVID-19.
汉传杂菓颗粒(HCZPs)是一种传统的配方,已被广泛用于治疗 2019 年冠状病毒病(COVID-19)。然而,其活性成分仍不清楚。在这里,我们使用基于表面等离子体共振(SPR)生物传感器的活性成分识别系统(SPR-AIRS)研究了靶向 SARS-CoV-2 刺突受体结合域(S-RBD)的 HCZP 成分。通过胺偶联将重组 S-RBD 蛋白固定在 SPR 芯片上,用于预筛选九种 HCZP 草药。超高效液相色谱-串联质谱(UPLC-MS/MS)从玫瑰中鉴定出鞣酸(GA)和甲基没食子酸(MG)为 S-RBD 配体,SPR 显示其 K 值分别为 2.69 和 0.95 μM。分子动力学表明,GA 与 S-RBD 的 G496、N501 和 Y505 形成氢键,MG 与 G496 和 Y505 形成氢键,抑制 S-RBD 与血管紧张素转化酶 2(ACE2)结合。基于 SPR 的竞争分析验证了这两种化合物都能阻断 S-RBD 和 ACE2 的结合,SPR 还表明 GA 和 MG 与 ACE2 结合(K 值分别为 5.10 和 4.05 μM),表明它们阻断了受体并中和了 SARS-CoV-2。SARS-CoV-2 假病毒感染表明,GA 和 MG 抑制了病毒进入 293T-ACE2 细胞。这些 S-RBD 抑制剂具有药物设计的潜力,同时为 HCZP 的组成及其在治疗 COVID-19 中的应用提供了参考。